Amgen (AMGN) Q1 2025: 14% Volume Surge Drives 35% Biosimilars Growth, Pipeline Execution Accelerates

May 1, 2025 | By EarningsIQ Research

Amgen’s first quarter delivered a decisive volume-driven acceleration, with broad-based momentum across general medicine, rare disease, inflammation, and oncology. The company’s biosimilars business surged, and pipeline execution advanced with multiple positive Phase III readouts and new launches. Investors should monitor the mounting R&D investments and evolving payer dynamics as Amgen leans into late-stage programs and navigates tariff and tax uncertainty.

Summary

  • Pipeline Depth: Multiple Phase III readouts and new launches signal broad late-stage momentum.
  • Biosimilars Expansion: 35% YoY biosimilar growth highlights portfolio diversification and execution edge.
  • R&D Investment Surge: Increased late-stage spend reflects a deliberate push into high-potential assets.

Performance Analysis

Amgen’s Q1 was marked by a robust 14% volume growth, underpinning an 11% rise in global product sales and a 9% revenue increase, as the company capitalized on strong demand across its diversified portfolio. Fourteen products posted double-digit gains, spanning general medicine, rare disease, inflammation, and oncology, underscoring the breadth of the company’s market reach. Biosimilars revenue stood out, growing 35% year-over-year to $735 million, driven by new launches such as PavBlue (ILEA biosimilar), Weslana (Stelara biosimilar), and Bekemvi (Solaris biosimilar), with PavBlue alone hitting $99 million in its first quarter.

Margin performance was resilient, with a 45.7% non-GAAP operating margin, above prior guidance due to R&D timing. However, net selling price declined 6%, reflecting payer pressure and competitive dynamics. R&D investment rose 12% YoY in Q1 and is expected to accelerate to 20% for the full year, as Amgen funds late-stage programs like Maritide (obesity), Olpaceran (cardiometabolic), and expanding rare disease assets. Free cash flow reached $1 billion for the quarter, supporting both pipeline investment and $400 million in capital expenditures across manufacturing sites.

  • Portfolio Breadth: 14 medicines with double-digit growth signals demand resilience and commercial execution.
  • Biosimilars Outperformance: Strong uptake in new launches and robust pipeline reinforce Amgen’s leadership in biosimilars.
  • Pricing Pressure: 6% net selling price decline highlights payer and competitive headwinds, especially in the U.S.

Amgen’s growth is increasingly driven by volume and new launches, while margin management and payer dynamics remain critical watchpoints as the company scales late-stage R&D investment.

Executive Commentary

"This was an exciting quarter, not just because of the financial results, but because of what those results signal about our future. Inline brands are delivering. We're advancing positive phase three studies. We're launching new products. We're earning breakthrough designations, and we're initiating the next wave of late-stage programs. We're operating in a volatile environment, but what hasn't changed is the growing patient demand for our medicines and the unwavering focus of our people. Amgen is well positioned to deliver innovation and growth, not just this year, but for the long term."

Bob Bradley, Call Leader

"We are reaffirming our 2025 total revenue guidance in the range of $34.3 billion to $35.7 billion. We now expect non-GAAP R&D expense to grow approximately 20% in 2025 versus growing mid-teens previously, reflecting increased investments to advance key late-stage pipeline assets, including Meritide and Opaceran. We continue to focus on execution excellence across the enterprise and remain well-positioned for sustained growth through the long term."

Peter Griffith, Financial Update Presenter

Strategic Positioning

1. General Medicine: Expanding Access and Penetration

Repatha, a PCSK9 inhibitor for cholesterol reduction, posted 27% global growth (42% U.S. volume growth), propelled by expanded primary care prescribing and improved payer access. Avenity, a bone health therapy, delivered 29% global growth, yet less than 250,000 U.S. patients have been treated, leaving a large untapped market. Amgen’s focus on direct-to-consumer outreach and prescriber education is driving incremental volume and positioning these brands for sustained expansion.

2. Rare Disease: Early Lifecycle, Global Expansion

Amgen’s rare disease portfolio—anchored by Tepeza, Cristexa, Uplizna, and Tavneos— is early in its growth curve. Uplizna’s recent FDA approval for IgG4-related disease (a newly coded autoimmune condition) and pending data in generalized myasthenia gravis (GMG) expand addressable markets. International launches, notably for Tepeza in Japan and soon the EU, are expected to drive incremental growth. The company is leveraging longstanding rheumatology and autoimmune commercial infrastructure to accelerate uptake.

3. Inflammation and Oncology: Pipeline Execution and New Standards of Care

Tezspire, a TSLP-targeting biologic, is gaining share in severe asthma and is advancing into COPD and rhinosinusitis with nasal polyps, supported by strong Phase III data. Bispecific T-cell engager platform products, including Blinsyto and Imdeltra, are delivering double-digit growth and redefining standards in hematologic and solid tumors. Imdeltra’s recent Phase III win in small cell lung cancer positions it as a new standard of care, with global launches underway.

4. Biosimilars: First-Wave Launch Strategy and Market Penetration

Amgen’s biosimilars business, now contributing over $700 million per quarter, is anchored by a strategy of early market entry and reliable supply. Recent U.S. launches (PavBlue, Weslana, Bekemvi) are gaining traction, aided by favorable reimbursement (Q-code for PavBlue) and strong prescriber feedback. The next wave of biosimilars, targeting blockbuster biologics like Opdivo and Keytruda, is advancing in Phase III, positioning Amgen for sustained biosimilar leadership.

5. R&D and Capital Allocation: Deliberate Investment in Late-Stage Pipeline

R&D spend is set to rise 20% in 2025, reflecting a deliberate pivot to late-stage assets with large market potential—especially Maritide (obesity) and Olpaceran (cardiovascular). The company is also investing heavily in U.S. manufacturing, with $2 billion in new expansions in Ohio and North Carolina, and is on track to realize $500 million in cost synergies from the Horizon acquisition by year-end. Debt reduction remains a priority, with $10.8 billion retired since the Horizon deal.

Key Considerations

Amgen’s Q1 results highlight a business executing across multiple fronts, but also navigating evolving risk factors:

Key Considerations:

  • Volume-Led Growth: High-volume expansion is offsetting net price declines, but continued payer pressure could challenge margin stability.
  • Late-Stage Pipeline Bets: Increased R&D intensity signals confidence in assets like Maritide (obesity) and Olpaceran (cardiometabolic), but also raises execution risk and spending scrutiny.
  • Biosimilars Differentiation: First-wave launch strategy and device innovation (pre-filled syringe) are key to biosimilar uptake, but competitive intensity is rising as more entrants target major biologics.
  • Rare Disease Commercialization: Early-stage launches in rare disease require significant prescriber education and patient identification, especially where diagnostic pathways are newly established (IgG4-related disease).
  • Manufacturing and Policy Exposure: Significant U.S. manufacturing investment positions Amgen to navigate potential tariff and tax changes, but policy outcomes remain uncertain.

Risks

Amgen faces mounting R&D expense, payer-driven pricing pressure, and uncertainty around U.S. tariffs and tax policy. Execution risk is elevated as the company leans into late-stage pipeline assets and expands into new indications and geographies. Competitive threats from both branded and biosimilar entrants, especially in obesity, PCSK9, and oncology, remain persistent headwinds.

Forward Outlook

For Q2 2025, Amgen guided to:

  • Continued double-digit volume growth across key brands and biosimilars
  • R&D expense acceleration as late-stage trials scale

For full-year 2025, management reaffirmed guidance:

  • Total revenue of $34.3 billion to $35.7 billion
  • Non-GAAP EPS of $20.00 to $21.20
  • R&D expense growth of ~20% (up from mid-teens prior)
  • Non-GAAP operating margin of ~46%

Management highlighted several factors that will shape the year:

  • Timing of R&D spend, with major investments weighted to Q2 and beyond
  • Potential fluctuations in biosimilar sales due to order timing (notably Weslana in Q2)

Takeaways

Amgen’s Q1 2025 shows a business leveraging volume and new launches to offset pricing headwinds, while doubling down on late-stage R&D and biosimilar leadership.

  • Volume and Pipeline Drive Near-Term Growth: Broad-based uptake across the portfolio and strong biosimilar launches support top-line expansion, but margin management is increasingly dependent on operational discipline and payer negotiations.
  • Strategic R&D Investment Sets the Stage: The step-up in R&D spend is a calculated bet on high-value assets, but will require disciplined execution and clinical success to deliver long-term returns.
  • Investor Focus: Monitor R&D milestones, biosimilar market share, and evolving policy risks—especially as Amgen’s growth story shifts from legacy brands to pipeline execution and global expansion.

Conclusion

Amgen’s first quarter underscores a business in transition—successfully scaling new launches and pipeline assets while navigating cost, pricing, and policy headwinds. The company’s ability to convert late-stage R&D into commercial growth, while managing rising investment and competitive risk, will define its trajectory through 2025 and beyond.

Industry Read-Through

Amgen’s strong biosimilar growth and rapid launch cadence signal intensifying competition for legacy biologics, putting pressure on both originators and late entrants. The company’s deliberate R&D pivot into obesity and rare disease mirrors broader industry trends, as big pharma chases high-value, specialty indications and durable franchises. Manufacturing investment and policy navigation are top-of-mind across the sector, with Amgen’s U.S. buildout reflecting a defensive posture against tariff and tax uncertainty. Investors should watch for further volume-driven growth and margin compression as payers and competition reshape the biopharma landscape.

AMGN Healthcare Biotechnology Biosimilars Obesity R&D Rare disease Pipeline